# Title

 Food and Drugs. PART 4â€”REGULATION OF COMBINATION PRODUCTS


# ID

 CFR-2018-title21-vol1.Pt. 4


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                |
|:------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['within', 'no later than']                                                                                                                                                                                           |
| Duration    | ['15 day', '30.0 day', '5 day', '5.0 day', '15.0 day']                                                                                                                                                                |
| Condition   | ['where', 'unless', 'subject to', 'when', 'if']                                                                                                                                                                       |
| Entities    | ['Device', 'Calculation', 'Type', 'Drug', 'Agency', 'Abbreviated', 'Food', 'Expiration', 'Biological', 'Humanitarian', 'Design', 'Malfunction', 'New', 'Paragraph', 'Manufacture', 'Reserve', 'Application', 'Field'] |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                        |
|:--------------|:-------------------------------------------------------------------------------------------------------------------------------|
| within        | manufacturing practice operating system means the operating system within an establishment that is designed and implemented to |
| within        | a combination product is considered a finished device within  the meaning of the QS regulation.                                |
| within        | a combination product is considered a drug product within  the meaning of the drug CGMPs.                                      |
| within        | report is a report required to be submitted within 15 days as described in &#167;&#8201;314.80 of this                         |
| within        | &#167;&#8201;314.80 of this chapter, which must be submitted within 30 calendar days instead of 15 calendar days               |
| within        | &#167;&#8201;600.80 of this chapter, which must be submitted within 30 calendar days instead of 15 calendar days               |
| no later than | other constituent part applicant(s) for the combination product no later than 5 calendar days of your receipt of the           |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|:-----------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 15 day     | Fifteen-day report is a report required to be submitted within 15 days as described in &#167;&#8201;314.80 of this chapter or &#167;&#8201;600.80 of this chapter, as well as followup reports to such a report.                                                                                                                                                                                                                                                                                         |
| 15.0 day   | Fifteen-day report is a report required to be submitted within 15 days as described in &#167;&#8201;314.80 of this chapter or &#167;&#8201;600.80 of this chapter, as well as followup reports to such a report.                                                                                                                                                                                                                                                                                         |
| 5 day      | Five-day report is a report as described in &#167;&#167;&#8201;803.3 and 803.53 of this chapter, as well as supplemental or followup reports to such a report as described in &#167;&#8201;803.56 of this chapter.                                                                                                                                                                                                                                                                                       |
| 5 day      | (1) If your combination product contains a device constituent part, you must submit:                                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (i) Five-day reports;                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |               (ii) Malfunction reports; and                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (iii) Correction or removal reports, and maintain records as described in &#167;&#8201;806.20 of this chapter for corrections and removals not required to be reported.                                                                                                                                                                                                                                                                                                                    |
| 15 day     | (2) If your combination product contains a drug constituent part, you must submit:                                                                                                                                                                                                                                                                                                                                                                                                                       |
|            |               (i) Field alert reports; and                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (ii) Fifteen-day reports as described in &#167;&#8201;314.80 of this chapter, which must be submitted within 30 calendar days instead of 15 calendar days if your combination product received marketing authorization under a device application.                                                                                                                                                                                                                                         |
| 30.0 day   | (2) If your combination product contains a drug constituent part, you must submit:                                                                                                                                                                                                                                                                                                                                                                                                                       |
|            |               (i) Field alert reports; and                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (ii) Fifteen-day reports as described in &#167;&#8201;314.80 of this chapter, which must be submitted within 30 calendar days instead of 15 calendar days if your combination product received marketing authorization under a device application.                                                                                                                                                                                                                                         |
| 15.0 day   | (2) If your combination product contains a drug constituent part, you must submit:                                                                                                                                                                                                                                                                                                                                                                                                                       |
|            |               (i) Field alert reports; and                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (ii) Fifteen-day reports as described in &#167;&#8201;314.80 of this chapter, which must be submitted within 30 calendar days instead of 15 calendar days if your combination product received marketing authorization under a device application.                                                                                                                                                                                                                                         |
| 15 day     | (ii) Fifteen-day reports as described in &#167;&#8201;600.80 of this chapter, which must be submitted within 30 calendar days instead of 15 calendar days if your combination product received marketing authorization under a device application.                                                                                                                                                                                                                                                       |
| 30.0 day   | (ii) Fifteen-day reports as described in &#167;&#8201;600.80 of this chapter, which must be submitted within 30 calendar days instead of 15 calendar days if your combination product received marketing authorization under a device application.                                                                                                                                                                                                                                                       |
| 15.0 day   | (ii) Fifteen-day reports as described in &#167;&#8201;600.80 of this chapter, which must be submitted within 30 calendar days instead of 15 calendar days if your combination product received marketing authorization under a device application.                                                                                                                                                                                                                                                       |
| 5.0 day    | (a) When you receive information regarding an event that involves a death or serious injury as described in &#167;&#8201;803.3 of this chapter, or an adverse experience as described in &#167;&#8201;314.80(a) of this chapter or &#167;&#8201;600.80(a) of this chapter, associated with the use of the combination product, you must provide the information to the other constituent part applicant(s) for the combination product no later than 5 calendar days of your receipt of the information. |


## Condition

| Condition   | Context                                                                                                                                             |
|:------------|:----------------------------------------------------------------------------------------------------------------------------------------------------|
| subject to  | Such an HCT/P is  subject to part 1271 of this chapter and is also                                                                                  |
| if          | constituent part to which those requirements would apply if that constituent part were not part of a                                                |
| if          | (b) of this section, the following requirements apply: if                                                                                           |
| if          | be made: (i) Section 820.20 of this chapter. if                                                                                                     |
| if          | be made: (i) Section 211.84 of this chapter. if                                                                                                     |
| if          | the other applicable manufacturing requirements listed under &#167;&#8201;4.3, if the combination product includes a biological product constituent |
| if          | the other applicable manufacturing requirements listed under &#167;&#8201;4.3, if the combination product includes a biological product constituent |
| if          | current good manufacturing practice requirements listed under &#167;&#8201;4.3, if the combination product includes an HCT/P, the current           |
| if          | current good manufacturing practice requirements listed under &#167;&#8201;4.3, if the combination product includes an HCT/P, the current           |
| when        | with paragraph (b) of this section may begin. when                                                                                                  |
| unless      | &#167;&#8201;4.3, supplement, and do not supersede, each other unless  the regulations explicitly provide otherwise.                                |
| unless      | 600, 606, 803, and 806 of this chapter, unless  a regulation explicitly provides otherwise.                                                         |
| if          | reporting requirements applicable to you that are ident if ied in this section apply to your constituent                                            |
| unless      | submit a report as specified in this paragraph unless you have already submitted a report in accordance                                             |
| if          | of this chapter with respect to your product. if                                                                                                    |
| if          | of this chapter with respect to your product. if                                                                                                    |
| if          | of this chapter with respect to your product. if                                                                                                    |
| unless      | submit a report as specified in this paragraph unless you have already submitted a report in accordance                                             |
| unless      | submit a report as specified in this paragraph unless you have already submitted a report in accordance                                             |
| if          | corrections and removals not required to be reported. if                                                                                            |
| if          | submit: (i) Field alert reports; and (ii) F if teen-day reports as described in &#167;&#8201;314.80 of this                                         |
| if          | submit: (i) Field alert reports; and (ii) F if teen-day reports as described in &#167;&#8201;314.80 of this                                         |
| if          | must submit: (i) Biological product deviation reports; and if                                                                                       |
| if          | (ii) F if teen-day reports as described in &#167;&#8201;600.80 of this                                                                              |
| if          | a summary and analysis of the reports ident if ied in paragraphs (c)(1)(i) and (ii) of this                                                         |
| if          | you must submit reports regarding postmarketing safety events if  not                                                                               |
| if          | you must submit reports regarding postmarketing safety events if  not                                                                               |
| if          | We will spec if y what safety information is needed and will                                                                                        |
| when        | calendar days of your receipt of the information. when                                                                                              |
| where       | How and  where must you submit postmarketing safety reports for your                                                                                |
| if          | safety reports in accordance with the regulations ident if ied in &#167;&#8201;4.102(b) that are applicable to your                                 |
| if          | reports required under &#167;&#8201;4.102 in the manner spec if ied in the regulation applicable to the type                                        |
| if          | reports required under &#167;&#8201;4.102 in the manner spec if ied in the regulation applicable to the type                                        |
| if          | reports required under &#167;&#8201;4.102 in the manner spec if ied in the regulation applicable to the type                                        |
| if          | You must submit the postmarketing safety reports ident if ied in &#167;&#8201;4.102(c)(2)(ii) and (c)(3)(ii) in accordance with                     |
| if          | (a) If you are a constituent part applicant: if                                                                                                     |
| if          | the regulations applicable to your product under &#167;&#8201;4.102. if                                                                             |


## Entities

| Entities     | Context                                                                          |
|:-------------|:---------------------------------------------------------------------------------|
| Food         | Food  and Drugs.                                                                 |
| Biological   | Biological product has the meaning set forth in &#167;&#8201;3.2(d)              |
| Device       | Device has the meaning set forth in &#167;&#8201;3.2(f) of                       |
| Drug         | Drug has the meaning set forth in &#167;&#8201;3.2(g) of                         |
| Manufacture  | Manufacture includes, but is not limited to, designing, fabricating,             |
| Type         | Type of constituent part refers to the category of                               |
| Paragraph    | part included in the combination product; or (2) Paragraph  (b) of this section. |
| Design       | Design  controls.                                                                |
| Calculation  | Calculation  of yield.                                                           |
| Expiration   | Expiration  dating.                                                              |
| Reserve      | Reserve  samples.                                                                |
| Abbreviated  | Abbreviated new drug application (ANDA) has the same meaning                     |
| Agency       | Agency  or we means Food and Drug Administration.                                |
| Application  | Application means, for purposes of this subpart, a BLA,                          |
| Biological   | Biological product has the meaning given the term in                             |
| Biological   | Biological product deviation report (BPDR) is a report as                        |
| Device       | Device has the meaning given the term in section                                 |
| Device       | Device application means a PMA, PDP, premarket notification submission,          |
| Drug         | Drug has the meaning given the term in section                                   |
| Field        | Field alert report is a report as described in                                   |
| Humanitarian | Humanitarian device exemption (HDE) has the meaning given the                    |
| Malfunction  | Malfunction report is a report as described in &#167;&#8201;803.50               |
| New          | New drug application (NDA) has the meaning given the                             |


